The price you pay for Cimzia may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the cost ...

Cimzia (certolizumab) is a prescription drug used to treat some types of arthritis and other conditions. Cimzia can cause side effects that range from mild to serious. Examples include infection ...

The US FDA has approved a label extension for UCB’s Cimzia (certolizumab pegol) for adults with moderate-to-severe plaque psoriasis, marking the company’s entry into immuno-dermatology ...

In April 2008, certolizumab pegol (Cimzia; UCB), a tumour-necrosis factor blocker, was approved by the US FDA for the treatment of adult patients with moderate-to-severe Crohn's disease who have ...

For now analysts aren’t wholly convinced, with sales predictions coming in at a modest $222 million in 2023, at a time when Cimzia is expected to be knocking on the door of €1.7 billion ($1.88 ...

Acquisitions of Celltech (2004) and Schwarz Pharma (2006) strengthened the biopharmaceutical pipeline, bringing in late-stage assets that would eventually be approved as Cimzia (immunology ...

and certolizumab pegol (Cimzia; UCB). “Those approvals came with a pound of flesh; at one point they may have seemed in doubt but finally got squeezed out of the FDA's doors. So, in no way do I ...